Abstract
Methotrexate and misoprostol have been shown in preliminary studies to be effective for abortion at ≤56 days gestation with minimal side effects. RU-486 is used in combination with prostaglandin for abortion ≤49 days gestation in France but ≤63 days gestation in England. This pilot study was performed to evaluate if methotrexate and misoprsotol may also be effectve up to 63 days gestation. Ten pregnant women between 57-63 days gestation were treated with methotrexate 50 mg/m2 intramuscularly followed 3 days later by misoprostol 800 μg vaginally. Abortion occurred in 6 women; abortion occurred in one of the women after a repeat dose of misoprostol 24 hours after the first dose. The remaining 4 women all had a surgical abortion. In the successfully treated women, vaginal bleeding lasted 14 ± 4 (mean ± standard deviation) days and serum β-hCG was ≤25 IU/L by 32 ± 5 days after the methotrexate injection. No methotrexate side effects occurred. Methotrexate and misoprostol do not appear to be as effective for medical abortion between 57 and 63 days gestation as compared to ≤56 days gestation.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 511-515 |
| Number of pages | 5 |
| Journal | Contraception |
| Volume | 50 |
| Issue number | 6 |
| DOIs | |
| State | Published - 1994 |
Fingerprint
Keywords
- Medical abortion
- methotrexate
- misoprostol
- vaginal ultrasound
- β-hCG
ASJC Scopus subject areas
- Medicine(all)
- Obstetrics and Gynecology
Cite this
Methotrexate and misoprostol for abortion at 57-63 days gestation. / Creinin, Mitchell D.
In: Contraception, Vol. 50, No. 6, 1994, p. 511-515.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Methotrexate and misoprostol for abortion at 57-63 days gestation
AU - Creinin, Mitchell D
PY - 1994
Y1 - 1994
N2 - Methotrexate and misoprostol have been shown in preliminary studies to be effective for abortion at ≤56 days gestation with minimal side effects. RU-486 is used in combination with prostaglandin for abortion ≤49 days gestation in France but ≤63 days gestation in England. This pilot study was performed to evaluate if methotrexate and misoprsotol may also be effectve up to 63 days gestation. Ten pregnant women between 57-63 days gestation were treated with methotrexate 50 mg/m2 intramuscularly followed 3 days later by misoprostol 800 μg vaginally. Abortion occurred in 6 women; abortion occurred in one of the women after a repeat dose of misoprostol 24 hours after the first dose. The remaining 4 women all had a surgical abortion. In the successfully treated women, vaginal bleeding lasted 14 ± 4 (mean ± standard deviation) days and serum β-hCG was ≤25 IU/L by 32 ± 5 days after the methotrexate injection. No methotrexate side effects occurred. Methotrexate and misoprostol do not appear to be as effective for medical abortion between 57 and 63 days gestation as compared to ≤56 days gestation.
AB - Methotrexate and misoprostol have been shown in preliminary studies to be effective for abortion at ≤56 days gestation with minimal side effects. RU-486 is used in combination with prostaglandin for abortion ≤49 days gestation in France but ≤63 days gestation in England. This pilot study was performed to evaluate if methotrexate and misoprsotol may also be effectve up to 63 days gestation. Ten pregnant women between 57-63 days gestation were treated with methotrexate 50 mg/m2 intramuscularly followed 3 days later by misoprostol 800 μg vaginally. Abortion occurred in 6 women; abortion occurred in one of the women after a repeat dose of misoprostol 24 hours after the first dose. The remaining 4 women all had a surgical abortion. In the successfully treated women, vaginal bleeding lasted 14 ± 4 (mean ± standard deviation) days and serum β-hCG was ≤25 IU/L by 32 ± 5 days after the methotrexate injection. No methotrexate side effects occurred. Methotrexate and misoprostol do not appear to be as effective for medical abortion between 57 and 63 days gestation as compared to ≤56 days gestation.
KW - Medical abortion
KW - methotrexate
KW - misoprostol
KW - vaginal ultrasound
KW - β-hCG
UR - http://www.scopus.com/inward/record.url?scp=0028607349&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028607349&partnerID=8YFLogxK
U2 - 10.1016/0010-7824(94)90010-8
DO - 10.1016/0010-7824(94)90010-8
M3 - Article
C2 - 7705094
AN - SCOPUS:0028607349
VL - 50
SP - 511
EP - 515
JO - Contraception
JF - Contraception
SN - 0010-7824
IS - 6
ER -